TARS derived from Akkermansia muciniphila or fragment thereof, and use thereof

Abstract

The present invention relates to uses of threonyl-tRNA synthetase (TARS) derived from Akkermansia muciniphila or a fragment thereof as an active ingredient for prevention, alleviation, and treatment of an inflammatory disease. The Akkermansia muciniphila TARS or a fragment thereof according to the present invention promotes the differentiation of M2 macrophages, which are anti-inflammatory macrophages, to multiply macrophages, thereby increasing the secretion of IL-10 as an anti-inflammatory cytokine, leading to the proliferation of B cells to result in an anti-inflammatory effect, and thus was verified to show alleviation effects of not only inflammatory diseases but also immune diseases, infectious diseases, and metabolic diseases accompanied by inflammation, and to have excellent effects in the prevention or treatment of an inflammatory bowel disease (IBD).

Dependencies are inferred from the claim text.